A Multicenter, Open-label, Randomized, Active-controlled, Phase 2 Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Intravenous BV100 Combined With Polymyxin B Versus Best Available Therapy in Adult Patients With Ventilator-associated Bacterial Pneumonia Suspected or Confirmed to be Due to Carbapenem-resistant Acinetobacter Baumannii
Latest Information Update: 17 Jan 2025
Price :
$35 *
At a glance
- Drugs Rifabutin (Primary) ; Polymixin B
- Indications Ventilator associated pneumonia
- Focus Pharmacokinetics
- Sponsors BioVersys
- 14 Jan 2025 Status changed from active, no longer recruiting to completed.
- 16 Oct 2024 According to a BioVersys AG media release, Company announced the completion of the last patient's last visit in the Phase 2 clinical trial in Ventilator Associated Bacterial Pneumonia (VABP)
- 16 Oct 2024 According to a BioVersys AG media release, top line results from the trial are expected in early 2025 once analysis of the data has been finalized.